| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.06 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.06 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.06 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.094 | 0.07 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.067 | 0.07 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.094 | 0.07 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.088 | 0.07 |